MEDINCELL S.A. financials
MEDINCELL S.A.
Country: FR Reporting currency: EUR Latest annual report: 2026-03-31
LEI:
969500R79U6PXCL2FF46 Financial statements
(EUR, as reported — unscaled; 108 line items across 2 annual periods)
| Line item | 2026 | 2025 |
|---|---|---|
| Income statement | ||
| Revenue | €24.3M | €27.7M |
| Cost of sales | €0 | €0 |
| Other income | €4.8M | €2.3M |
| Distribution costs | €4.2M | €3.3M |
| Administrative expenses | €14.3M | €10.9M |
| Operating expenses | €45.0M | €38.5M |
| Operating profit (EBIT) | -€20.8M | -€10.8M |
| Net finance income / (cost) | -€10.6M | -€7.4M |
| Profit before tax | -€31.4M | -€18.3M |
| Income tax expense | -€69.0K | €160.0K |
| Profit for the year | -€31.3M | -€18.4M |
| — attributable to owners | -€31.3M | -€18.4M |
| — attributable to NCI | €0 | €0 |
| Total comprehensive income | -€31.3M | -€18.3M |
| Per share | ||
| Basic EPS | €-0.94 | €-0.62 |
| Diluted EPS | €-0.94 | €-0.62 |
| Free cash flow / share | €-0.76 | €0.63 |
| Cash flow statement | ||
| Net cash from operating activities | -€24.6M | €19.5M |
| Net cash from investing activities | -€10.5M | -€13.2M |
| Purchase of PP&E (capex) | €815.0K | €747.0K |
| Purchase of intangibles | €1.2M | €913.0K |
| Net cash from financing activities | €38.8M | €33.3M |
| Proceeds from borrowings | €570.0K | €0 |
| Repayments of borrowings | €4.7M | €4.1M |
| Lease liability payments | €710.0K | €704.0K |
| Balance sheet | ||
| Total assets | €108.1M | €90.5M |
| Non-current assets | €11.3M | €9.8M |
| Property, plant & equipment | €2.4M | €2.3M |
| Right-of-use assets | €2.6M | €2.9M |
| Current assets | €96.7M | €80.6M |
| Trade & other receivables | €4.5M | €3.1M |
| Cash & equivalents | €62.8M | €59.0M |
| Total equity | €3.1M | -€16.4M |
| — attributable to owners | €3.1M | -€16.4M |
| Non-controlling interests | €0 | €0 |
| Non-current liabilities | €84.3M | €76.9M |
| Lease liabilities (non-current) | €1.7M | €2.0M |
| Current liabilities | €20.7M | €29.9M |
| Lease liabilities (current) | €667.0K | €673.0K |
| Trade & other payables | €3.4M | €4.0M |
| Derived metrics | ||
| Free cash flow | -€25.4M | €18.7M |
| Operating margin | -85.6% | -39.1% |
| Net margin | -128.9% | -66.5% |
| Return on equity | -1021.1% | 112.7% |
| Cash conversion ratio | 0.78× | -1.06× |
| Capex coverage | -30.13× | 26.06× |
| Other reported items | ||
| Adjustments For Decrease Increase In Other Operating Receivables | -€2.1M | -€44.0K |
| Adjustments For Decrease Increase In Trade Account Receivable | -€1.3M | -€893.0K |
| Adjustments For Depreciation and Amortisation Expense | €1.8M | €2.0M |
| Adjustments For Income Tax Expense | -€69.0K | €160.0K |
| Adjustments For Increase Decrease In Other Operating Payables | -€5.7M | €23.3M |
| Adjustments For Increase Decrease In Trade Account Payable | -€611.0K | €2.1M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | €40.0K | €156.0K |
| Adjustments For Provisions | -€28.0K | €1.1M |
| Adjustments For Sharebased Payments | €5.2M | €3.0M |
| Cash Flows From Used In Operations Before Changes In Working Capital | €16.5M | €13.5M |
| Comprehensive Income Attributable To Noncontrolling Interests | €0 | €0 |
| Comprehensive Income Attributable To Owners of Parent | -€31.3M | -€18.3M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €2.6M | €6.6M |
| Current Derivative Financial Liabilities | €0 | €0 |
| Current Provisions | €0 | €0 |
| Current Tax Assets Current | €86.0K | €0 |
| Current Tax Liabilities Current | €0 | €0 |
| Deferred Tax Assets | €0 | €0 |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | -€3.0K | €0 |
| Equity and Liabilities | €108.1M | €90.5M |
| Gains Losses On Exchange Differences On Translation Before Tax | €10.0K | €1.0K |
| Income Tax Relating To Remeasurements of Defined Benefit Plans of Other Comprehensive Income | €0 | €0 |
| Income Taxes Paid Refund Classified As Operating Activities | €17.0K | €160.0K |
| Increase Decrease In Cash and Cash Equivalents | €3.8M | €39.6M |
| Increase Decrease In Number of Ordinary Shares Issued | 2.4M | 3.3M |
| Increase Decrease In Working Capital | €9.8M | -€24.5M |
| Increase Decrease Through Appropriation of Retained Earnings | €0 | €0 |
| Increase Decrease Through Sharebased Payment Transactions | €5.2M | €3.0M |
| Increase Decrease Through Transfers and Other Changes Equity | €0 | — |
| Increase Decrease Through Treasury Share Transactions | €44.0K | €93.0K |
| Intangible Assets Other Than Goodwill | €3.5M | €2.6M |
| Interest Income On Cash and Cash Equivalents | €1.4M | €1.4M |
| Interest Paid Classified As Financing Activities | €1.9M | €1.7M |
| Interest Received Classified As Investing Activities | €1.4M | €1.4M |
| Investment Accounted For Using Equity Method | €15.0K | €15.0K |
| Issue of Equity | €44.9M | €39.4M |
| Issued Capital | €359.0K | €331.0K |
| Losses On Change In Fair Value of Derivatives | €5.4M | €3.5M |
| Noncurrent Derivative Financial Liabilities | €14.5M | €8.6M |
| Noncurrent Provisions For Employee Benefits | €445.0K | €361.0K |
| Number of Shares Issued | 35.9M | 33.1M |
| Other Comprehensive Income | -€1.0K | €95.0K |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | -€11.0K | €94.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | -€11.0K | €94.0K |
| Other Current Financial Assets | €22.0M | €12.9M |
| Other Current Nonfinancial Assets | €7.3M | €5.6M |
| Other Current Nonfinancial Liabilities | €14.0M | €18.6M |
| Other Finance Cost | €1.1M | €230.0K |
| Other Finance Income | €43.0K | €0 |
| Other Inflows Outflows of Cash Classified As Investing Activities | -€653.0K | -€91.0K |
| Other Longterm Provisions | €2.8M | €2.9M |
| Other Noncurrent Financial Assets | €2.8M | €1.9M |
| Other Noncurrent Financial Liabilities | €52.4M | €49.4M |
| Other Noncurrent Nonfinancial Liabilities | €12.5M | €13.7M |
| Proceeds From Issuing Shares | €45.5M | €39.7M |
| Research and Development Expense | €26.5M | €24.3M |
| Reserve of Sharebased Payments | — | €598.0K |
| Retained Earnings Excluding Profit Loss For Reporting Period | -€11.4M | -€69.0M |
| Retained Earnings Profit Loss For Reporting Period | -€31.3M | -€18.4M |
| Revenue From Contracts With Customers | €19.5M | €25.4M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | €0 | €0 |
| Share Premium | €45.4M | €70.7M |
Methodology
Every line item above is a fact tagged in MEDINCELL S.A.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.